

Index

A

- AMP, cyclic
 - macrophage-derived, 6
 - prostaglandin effect on, 24
- Aclacinomycin A
 - enzyme immunoassays of, 257, 258, 269
 - radioimmunoassay for, 269
 - in suppressor T cell elimination, 84
- Acquired immune deficiency syndrome, 227–228
- Actinomycin D, 268
- Adoptive immunotherapy
 - suppressor T cells in, 73–81
 - suppressor macrophages in, 34
- Adriamycin
 - enzyme immunoassay for, 257, 266–267
 - radioimmunoassay for, 252, 265–266
 - in suppressor T cell elimination, 84
 - toxicity of, 265
- Adult T cell leukemia, 132, 133
- Allograft reaction
 - cell-mediated immune function in, 171
 - in reproduction, 156
 - in transplantation immunology, 155
- Alpha-fetoprotein, 168
- Antibodies
 - in acute lymphoblastic leukemia, 132
 - to anticancer drugs, 253–254, 258–259
 - to carcinoembryonic antigens, 157
 - in erythroblastosis fetalis, 172
 - to granulocytes, 238–240
 - in immunoregulation, 6–7
 - in lymphocytic leukemia, chronic, 137
 - monoclonal. *See* Monoclonal antibodies
 - in multiple myeloma, 140, 141
 - to platelets, 218, 219
 - in pregnancy, 166
 - in tumor development, 158–159
- Anticancer drugs
 - aclacinomycin A. *See* Aclacinomycin A
 - actinomycin D, 269
 - adriamycin. *See* Adriamycin
 - antibodies to, 253–254, 258–259
 - 1- β -D-arabinofuranosylcytosine, 84, 269–270
 - 1- β -D-arabinofuranosyluracil, 270–271
 - bleomycin. *See* Bleomycin
 - bruceantin, 276
 - chromomycin A3, 258, 268–269
 - 2,3-dihydro-1H-imidazol[1,2-b]pyrazole, 276–277
 - doxorubicin, 265–267
 - 5-fluorodeoxyuridine, 271
 - 7-*N*-(*p*-hydroxyphenyl)mitomycin C (M-83), 262
 - immunoassays methods for, 252–261
 - detection of drug-specific antibodies in, 258–259
 - enzyme immunoassay. *See* Enzyme immunoassays
 - general principles of, 252–253
 - radioimmunoassay. *See* Radioimmunoassays
 - sensitivity of, 259–260
 - specificity of, 259
 - as immunogen, preparation of, 253–254
 - labeling of, 254–258
 - enzyme, 255–258
 - radioactive, 254–255
 - limitations of, 251–252
 - macromomycin, 268
 - methotrexate. *See* Methotrexate
 - mithramycin, 268–269
 - mitomycin C. *See* Mitomycin C
 - neocarzinostatin, 267–268
 - pepleomycin. *See* Pepleomycin
 - radioimmunoassays for, 252
 - tallysomycin, 265

- Anticancer drugs (*cont.*)
 vinblastine, 274–276
 vincristine, 274–276
- Antigen presenting cell
 function of, 4, 5
 macrophages as, 9
 ultraviolet radiation effect on, 65–66
- Antigens
 differentiation, 131
 embryonic/fetal, 156, 163–166
 alpha-fetoprotein, 168
 antibody coverage of, 166
 on cancer cells, 168–169
 carcinoembryonic, 157, 168–169
 fetal sulfoglycoprotein, 169
 immunological insertness of, 165–166
 loss of, 166
 pancreatic oncofetal antigen, 169
 granulocyte, 236, 237–240
 in helper/inducer cell activation, 5, 6
 in immunoregulation, 6–7
 melanoma-associated, 191, 201
 platelet, 218, 219
 processing and presentation of, 3
 in suppressor T cell activation, 5, 6
 trophoblast-specific, 165
 tumor. *See* Tumor antigens
 ultraviolet radiation effect on, 66
- Antisera
 to anticancer drugs, 253, 254, 259
 for suppressor T cell elimination, 71–73
- 1- β -D-Arabinofuranosylcytosine, 84, 269–270
- 1- β -D-Arabinofuranosyluracil, 270–271
- Arginase, macrophage-derived, 6
- B**
- B lymphocytes
 activation of, 3
 in acute lymphoblastic leukemia, 132
 in head and neck cancer, 144
 in lymphocytic leukemia, chronic, 137–138
 in metastatic spread of cancer, 161
 in multiple myeloma, 140–141
 in promyelocytic leukemia, 140
 in Sezary syndrome, 135
 suppressor T cell effect on, 57
 suppressor macrophage effect on, 27–28
- Bleeding disorders, 216
- Bleeding time, 215, 217
- Bleomycin
 enzyme immunoassays for, 257, 258
 pharmacokinetics of, 263–264
 radioimmunoassay for, 262–264
- in suppressor T cell elimination, 84, 87–88
 toxicity of, 262, 263
- Bone marrow ablation and transplantation, 212
- Breast cancer
 circulating immune complexes in, 189, 190
 immunoregulatory cell abnormalities in, 142–143
- Bruceantin, 276
- Busulfan, 84, 87
- C**
- Cancer
 alpha-fetoprotein in, 168
 breast, 142–143, 189, 199
 cells of. *See* Neoplastic cells
 chemotherapy for
 mucositis following, 216
 for suppressor macrophage elimination, 32–34
 for suppressor T cell elimination, 83–88
 colon, 144–145
 head and neck, 143–144
 immune complexes in, circulating, 190–203
 clinical significance of, 199–201
 cross target cell adsorption of, 196–197
 isolation and characterization of, 197–198
 monitoring of, 190–192
 pathogenic significance of, 200
 predictive value of, 198–199
 prognostic significance of, 199–200
 serial-sample study of, 193–196
 single-sample study of, 192, 193
 therapeutic significance of, 200–201
 immunotherapy for. *See* Immunotherapy
 leukemia. *See* Leukemia
 lung, 145, 190, 199
 metastatic. *See* Metastases
 ovarian, 199
 serum markers of, 189
 suppressor cells in metastatic spread of, 161
 transfusion therapy for, 212
 granulocyte. *See* Granulocyte transfusion therapy
 platelet. *See* Platelet transfusion therapy
- Carcinoembryonic antigen, 157, 168–169
- Chemotherapy
 mucositis following, 216
 for suppressor T cell elimination, 83–88
 for suppressor macrophage elimination, 32–34
- Choriocarcinoma, 172
- Chromomycin A3, 258, 268–269
- Cimetidine, 88

Colon cancer, 144–145

Cyclophosphamide

in suppressor macrophage activity inhibition, 32

in suppressor T cell elimination, 84–87

Cytoxan. *See* Cyclophosphamide

D

Daunomycin, 257, 258

Delayed-type hypersensitivity

macrophages in, 3, 6

T cells in, 37–40

Differentiation antigens, 131

2,3-Dihydro-1*H*-imidazo[1,2-*b*]pyrazole, 276–277

Disseminated intravascular coagulation syndrome, 216

Doxorubicin

enzyme immunoassay for, 266–267

radioimmunoassay for, 265–266

E

Endoxan. *See* Cyclophosphamide

Enzyme immunoassay, 252

for aclacinomycin A, 269

for adriamycin, 266–267

for chromomycin A3, 269

competitive, 260

detection of drug-specific antibodies in, 258

for doxorubicin, 266–267

homogenous, 260

7-*N*-(*p*-hydroxyphenyl)mitomycin C (M-83), 262

labeling of anticancer drugs for, 255–258

method of, 260

for methotrexate, 271–274

for mithramycin, 269

for mitomycin C, 261–262

for neocarzinostatin, 267–268

for olivomycin, 269

for pepleomycin, 265

radioimmunoassay vs, 261

for vinblastine, 276

for vincristine, 276

Erythroblastosis fetalis, 172

F

Fetal development

antigens on embryonic tissues in, 163–165

cellular mechanism in, 167

embryonic genes in, 170–171

erythroblastosis fetalis in, 172

humoral mechanism in, 166

immune enhancement with, 166–167

metabolic pattern of cells in, 167

migration of cells in, 167

runt disease during, 172

spontaneous abortion during, 172

tRNA of cells in, 168

trophoblast's immunological inertness in, 165–166

tumor development vs, 167–173

de-repression of embryonic genes in, 170–171

embryonic antigens on cancer cells in, 168

neoplastic cell and fetal cell similarities in, 167–168

nonrejection mechanisms in, 168–170

5-Fluorodeoxyuridine, 271

G

Gastrointestinal cancer, 189

Genetics

of cellular interactions of immune response, 3–4

of colon cancer, 144

of de-repression of embryonic genes in malignancy, 170–171

of lymphocytic leukemia, chronic, 138

of promyelocytic leukemia, 140

of suppressor cell cascade, 5

Graft-vs-host disease, 228

Granulocyte transfusion therapy, 229–240

alloimmunization from, 235, 236

amphotericin B interactions with, 236

with antibiotic therapy, 229, 230, 231

for cancer, 233

cytomegalovirus transmission via, 236–237

discontinuation of, indications for, 232

evaluation of response to, 230, 233–234

for fungal infections, 232

histocompatibility factors in, 237–240

indications for, 231–233

with pneumonia, 236

procurement of granulocytes for, 230–231

prophylactic, 233, 234–235

pulmonary complications of, 236

side effects of, 235–237

site of infection as factor in, 232

transfusion reaction from, 238

H

Head and neck cancer, 143–144

- Helper T cells**
 antigen presenting cells for, 6, 9
 function of, 3
 in Hodgkin's disease, 136–137
 in immunotherapy for suppressor T cell elimination, 81–83
 in lymphocytic leukemia, chronic, 137
 markers of, 132
 in promyelocytic leukemia, 140
 in Sezary syndrome, 135
 suppressor cell regulation of, 4, 5
 in tumor growth, 58
- Hepatitis, transfusion-induced, 227**
- Hodgkin's disease, 135–137**
- Human chorionic gonadotropin hormone**
 in fetal development, 165
 in tumor development, 157
- Hydrocortisone, 61, 88**
- 7-N-(*p*-Hydroxyphenyl)mitomycin C (M-83), 262**
- I**
- Immune complex**
 in cancer, 189–203
 clinical significance of, 199–201
 cross target cell adsorption of, 196–197
 isolation and characterization of, 197–198
 monitoring of, 190–192
 pathogenic significance of, 200
 predictive value of, 198–199
 prognostic significance of, 199–200
 serial-sample study of, 193–196
 single-sample study of, 192, 193
 therapeutic significance of, 200–201
 in complement activation, 200
 diagnostic value of, 189
 extracorporeal immunoadsorption clearance of, 200, 201
 plasmapheresis removal of, 200
 in pregnancy, protective effect of, 166, 167
 renal injuries from, 200
 in suppressor cell induction, 42–43
 tissue damage from, 200, 202
 in tumor development, 159, 160
- Immunoglobulins. *See also* Antibodies**
 in acute lymphoblastic leukemia, 132, 133
 in multiple myeloma, 140, 141
 in Sezary syndrome, 134
 in tumor growth, 158–159
- Immunotherapy**
 for suppressor T cell elimination, 71–90
 adoptive, 73–81
 alloantisera in, specific, 71–73
 cytotoxic drugs and blocking agents in, 83–88
 helper function in, 81–83
 irradiation in, 90
 thymoidectomy and splenectomy in, 88–90
 for suppressor macrophage elimination or blocking of action, 31–35
- Indomethacin, 25, 31**
- Interferon, macrophage-derived, 6**
- Interleukin, 1, 3**
- Interleukin 2**
 function of, 3
 in lymphocytic leukemia, chronic, 138, 139
 in promyelocytic leukemia, 140
 suppressor T cell effect on production of, 57, 58
- L**
- Leucovorin, 271, 274**
- Leukemia**
 adult T cell, 132, 133
 bone marrow ablation therapy for, 212
 circulating immune complex in, 190, 201
 fetal hemoglobin in, 168
 lymphoblastic, acute, 132–134
 lymphocytic, chronic, 137–139
 myelocytic, chronic, 229, 230–231
 progranulocytic, 216
 promyelocytic, 139–140
 prophylactic platelet transfusion for, 216, 218
 transfusion therapy for, 212
- Lung cancer, 145, 190, 199**
- Lymphocyte-activating factor, 3**
- Lymphocytes**
 antigenicity of, 213
 B. *See* B lymphocytes
 in platelet transfusion, 213
 T. *See* T lymphocytes.
- M**
- Macromycin, 268**
- Macrophage activating factor, 26**
- Macrophages**
 antitumor activities of, 9
 circulating immune complex and, 190, 198, 200
 in delayed-type hypersensitivity, 3, 6
 in head and neck cancer, 143
 in immune control mechanism, 6
 in lung cancer, 145
 in metastatic spread of cancer, 161

- suppressor, in tumor-bearing hosts, 6, 9–35
 activated vs primed, 16
 content of, 9–10
 cytotoxic drug effect on, 32–34
 different types of, collaboration between, 28–30
 efficiency of, 30
 experimental evidence for, 10–13
 functions and characteristics of, 18–23
 immunosuppressive factors of, 24–25
 immunotherapy based on, 31–35
 indomethacin effect on, 25
 irradiation effects on, 30–31
 in macrophage activating factor inhibition, 26
 mechanism of action of, 17–31
 in migration inhibitory factor inhibition, 26
 nonspecific effects of, 17, 24
 normal macrophages vs, 13–17
 prostaglandin derived from, 24–25
 prostaglandin-synthetase inhibitor effect on, 31–32
 protein synthesis effect of, 26
 specific vs nonspecific, 17
 splenic vs peritoneal, 28–30
 suppressor T cell interaction with, 43, 44
 target of, 26–28
 tumor proliferation inhibition via, 31
 vaccine effect on, 32–33
- Malignancies.** *See also* Cancer; Tumors
 cell differentiation abnormalities in, 156
 de-repression of embryonic genes in, 170–171
 immunoregulatory cell abnormalities in, 131–146
 of acute lymphoblastic leukemia, 132–134
 of breast cancer, 142–143
 of chronic lymphocytic leukemia, 137–139
 of colon cancer, 144–145
 of head and neck cancer, 143–144
 of Hodgkin's disease, 135–136
 of lung cancer, 145
 of multiple myeloma, 140–142
 of mycosis fungoides, 134–135
 of prolymphocytic leukemia, 139–140
 of Sezary syndrome, 134–135
 nonrejection mechanisms in, 169–170
 suppressor cells in, 2–101
 macrophages, 6, 9–35
 T cells, 35–90
 undefined, 90–96
- Melanoma, malignant**
 circulating immune complexes in, 189, 190
 clinical significance of, 199–201
 cross target cell adsorption of, 196–197
 isolation and characterization of, 197–198
 monitoring of, 190–192
 plasmapheresis removal of, 201
 predictive value of, 198–199
 prognostic significance of, 199–200
 serial-sample study of, 193–196
 single-sample study of, 192, 193
 therapeutic significance of, 201
 spontaneous regression of, 172
- Metastases**
 circulating immune complexes in
 clinical significance of, 199
 predictive value of, 198–199
 therapeutic significance of, 201
 monoclonal antibody targeting of, 201
 suppressor cells in, 161
- Methotrexate**
 enzyme immunoassay for, 271–274
 with leucovorin, 271
 radioimmunoassay for, 252, 271–274
- Migration inhibitory factor, 26, 94**
- Mithramycin, 268–269**
- Mitomycin C**
 enzyme immunoassays of, 257, 258, 261
 suppressor macrophage activity with, 30–31
 toxicity of, 261
- Monoclonal antibodies**
 in acute lymphoblastic leukemia, 133
 in breast cancer, 143
 in differentiation antigen identification, 131
 in head and neck cancer, 144
 in Hodgkin's disease, 136
 in lymphocytic leukemia, chronic, 137
 in melanoma, malignant, 191, 201
 in Sezary syndrome, 135
- Multiple myeloma**
 immunoregulatory cell abnormalities in, 140–142
 suppressor T cells in, 58–60
- Mycosis fungoides, 134–135**
- N**
- Natural killer cells**
 in breast cancer, 142, 143
 in colon cancer, 144–145
 in head and neck cancer, 144
 in Hodgkin's disease, 136
 immune complex effect on, 190
 in lymphocytic leukemia, chronic, 139

- Nazelof's syndrome, 134
 Neocarzinostatin, 267–268
 Neoplasms. *See* Cancer; Malignancies;
 Tumors
 Neoplastic cells
 anaerobic glycolysis of, 170
 embryonic antigens on, 168–169
 fetal cell similarities to, 156, 167–171
 metabolic pattern of, 167
 migration of, 167
 sialomucinous coating on, 157
 Neuraminidase tumor therapy, 157
 Neuroblastoma
 circulating immune complexes in, 189
 spontaneous regression of, 173
- O**
 Olivomycin, 268–269
 Oncofetal antigens, 169, 190, 191
 Oncogenic viruses
 in embryonic gene de-repression, 171
 immunological tolerance to antigens of, 158
 in suppressor T cell induction, 66–67
 Ovarian cancer, 199
- P**
 Pepleomycin
 enzyme immunoassays for, 257, 258, 265
 radioimmunoassay for, 265
 toxicity of, 264
 Plasmapheresis, 200–201
 Platelet transfusion therapy
 acquired immune deficiency syndrome from,
 227–228
 alloimmunization from, 213, 218–226
 diagnosis of, 218, 219
 dose-response relationship with, 220–222
 lymphocyte depletion effect on, 222–223
 removal of HLA antigens after, 226
 single donor effect on, 223–224
 transfusion approach after, 224–226
 transfusion reactions with, 213
 bleeding time tests for, 217
 circulatory congestion from, 227
 cryopreservation of platelets for, 228–229
 destruction of platelets with, 217, 218
 evaluation of response to, 217–218
 graft-vs-host disease from, 228
 HLA antigens in, 218–219
 alloimmunization from, 224–226, 227
 removal of, 226
 hazards of, 226–228
 indications for, 215–217
 infectious disease transmission by, 227
 with invasive diagnostic procedures, 217
 procurement of platelets for, 212–213
 prophylactic, 215–217
 alloimmunization from, 220
 effectiveness of, 217
 red blood cell contamination of, 213
 storage of platelets for, 214–215
 transfusion reactions from, 213, 226–227
 Polyamine oxidase, macrophage-derived, 6
 Polyinosinic-polycytidylic acid, 84
 Prostaglandins
 cAMP effect of, 24
 in colon cancer, 144
 in Hodgkin's disease, 136
 macrophage-derived, 6, 14, 24–25, 31
 suppressor T cell derived, 45
 in tumor growth, 31–32
 Puromycin, 257
- R**
 Radiation
 suppressor T cell activity after, 61–66, 90
 suppressor macrophage activity after, 30–31
 Radioimmunoassays
 for aclacinomycin A, 269
 for actinomycin D, 268
 for adriamycin, 252, 265–266
 for 1- β -D-arabinofuranosylcytosine, 270
 for 1- β -D-arabinofuranosyluracil, 271
 for bleomycin, 262–264
 for bruceatin, 276
 for 2,3-dihydro-1H-imidazol[1,2-b]pyrazole,
 276–277
 for doxorubicin, 265–266
 enzyme immunoassay vs, 261
 for 5-fluorodeoxyuridine, 271
 labeling of anticancer drugs for, 254–255
 for leucovorin, 274
 for macromycin, 268
 method for, 260
 for methotrexate, 252, 271–274
 for neocarzinostatin, 267–268
 for pepleomycin, 265
 for tallysomycin, 265
 for vinblastine, 275–276
 for vincristine, 275–276
 Red blood cells in platelet transfusion, 213
 Renal tumors, 172
 Reproduction
 allograft reaction in, 156
 fetal development in. *See* Fetal development
 nonrejection mechanisms in, 169–170
 Runt disease, maternal, 172

S

Sezary syndrome, 134–135
 Skin cancer, 61–66
 Soluble immune response suppressor, 6
 Splenectomy in suppressor T cell elimination, 88–90
 Suppressor T cells
 antigen presenting cells for, 9
 in breast cancer, 143
 contrasuppressor, 5
 functions and characteristics of, 48–55
 in helper/inducer cell regulation, 4, 5
 in Hodgkin's disease, 136–137
 in lung cancer, 145
 in lymphocytic leukemia, chronic, 137
 markers of, 132
 in multiple myeloma, 142
 in pregnancy, 167
 in promyelocytic leukemia, 140
 in tumor-bearing hosts, 35–90
 aclacinomycin A effect on, 84
 adoptive immunotherapy and, 73–81
 adriamycin effect on, 84
 alloantisera elimination of, 71–73
 allogeneic tumor cell induction of, 47–57
 bleomycin effect on, 84, 87–88
 busulfan effect on, 84, 87
 cellular target of, 57–58
 coexistence of macrophages with, 44
 cyclophosphamide effect on, 61, 84–87
 cytotoxic drugs and blocking agents against, 83–88
 delayed-type hypersensitivity response with, 37–40
 DNA synthesis inhibition by, 46
 experimental evidence for, 35
 heterogeneity of, 60–61
 hydrocortisone sensitivity of, 61, 88
 IL 2-producing T cells and, 57, 58
 immune complex induction of, 42–43
 immunotherapy based on elimination of, 71–90
 irradiation effect on, 90
 low dose tumor cell induction of, 46–47
 macrophage inhibition by, 42
 mechanism of action of, 36–61
 mixed lymphocyte reaction with, 46, 47, 56
 myeloma protein induction of, 58–60
 nonimmunogenic tumor induction of, 67–71
 oncogenic virus induction of, 66–67
 specific vs nonspecific, 35
 suppressive factors produced by, 44–46

 suppressor macrophage interaction with, 43, 44
 thymoidectomy and splenectomy effect on, 88–90
 tumor antigen induction of, 36
 ultraviolet irradiation induction of, 61–66
 types of, 4–5
 Suppressor cells
 in breast cancer, 142
 cytotoxicity of, 91
 in Hodgkin's disease, 135–136
 immune response with induction of, 90–96
 macrophages as. *See* Macrophages, suppressor
 malignancy and, 2–101
 in metastatic spread of cancer, 161
 T cells. *See* Suppressor T cells
 in tumor development, 160–162
 undefined, function and characteristics of, 92–93
 virus-transformed cells as, 94
 Surgery
 for circulating immune complex removal, 201
 for suppressor T cell elimination, 88–90

T

T lymphocytes
 activation of, 3
 in acute lymphoblastic leukemia, 132–134
 antigen presentation to, 3
 in B cell activation, 3
 in breast cancer, 142, 143
 in head and neck cancer, 143–144
 helper. *See* Helper T cells
 in Hodgkin's disease, 136
 immunoregulatory, identification of, 131
 in lung cancer, 145
 in lymphocytic leukemia, chronic, 137–139
 in multiple myeloma, 141–142
 in promyelocytic leukemia, 140
 in Sezary syndrome, 134, 135
 suppressor. *See* Suppressor T cells
 T-cell growth factor. *See* Interleukin 2
 Tallysomycin, 265
 Thrombocytopenia, 212, 215–217
 Thymidine
 in DNA synthesis, 6
 macrophage-derived, 6
 in suppressor cell activity measurements, 91
 Thymoidectomy in suppressor T cell elimination, 88–90

- Transfusion therapy
 granulocyte. *See* Granulocyte transfusion therapy
 platelet. *See* Platelet transfusion therapy
- Trophoblastic cells
 human chorionic gonadotropin hormone of, 157
 immunological inertness of, 165-166
 protective sialomucinous coating on, 157
- Tumor antigens
 carcinoembryonic, 157, 168-169
 circulating immune complex detection through, 199
 loss of, in tumor development, 157
 recognition of, 7, 156
 sialomucinous cell surface coating of, 157
 suppressor macrophage response to, 17
 suppressor T cell response to, 35, 36
 transplantation, tumor-specific, 158
 in tumor-growth enhancing factor generation, 161-163
 of ultraviolet radiation-induced tumors, 61-64
- Tumors. *See also* Cancer; Malignancies
 cells of. *See* Neoplastic cells
 development of, 156-163
 angiogenesis factor in, 167
 antigenicity of tumor cell surface in, 157-158
 cellular mechanism in, 160-163
 fetal development vs, 167-173
 human chorionic gonadotropin hormone in, 157
 humoral mechanism in, 158-160
 immunological enhancement with, 158
 sialomucinous tumor cell coating in, 157
 suppressor cells in, 160-161
 tumor growth-enhancing factors in, 161-163
 tumor-specific transplantation antigens in, 158
 immune response to, 7-9
 suppressor cell effect on, 2-101
 macrophages, 9-35
 T cells, 35-90
 undefined, 90-96
- V**
- Vaccines, tumor
 for malignant melanoma, 198
 neuraminidase in, 157
 in suppressor macrophage activity inhibition, 32-33
- Vinblastine, 274-276
 Vincristine, 274-276

Contents, Volume 1

- Chapter 1 Cells Responsible for Tumor Surveillance in Man:
Effects of Radiotherapy, Chemotherapy, and Biologic
Response Modifiers

*Peter Reizenstein, Claudio Ogier, Henric Blomgren,
Bjorn Petrini, and Jerzy Wasserman*

- Chapter 2 Immunity and Its Role in Conventional Cancer
Therapy

P.K. Ray, M. Sheshadri, and T.B. Poduval

- Chapter 3 Immunologic Methods of Diagnostic and Prognostic
Value in Tumor Bearers

Kenneth J. McCormick

- Chapter 4 Complement and Cancer: Activation of the
Alternative Pathway as a Theoretical Base for
Immunotherapy

Peter D. Cooper

- Chapter 5 Role of Carcinoembryonic Antigen Assay in the
Management of Cancer

Paul H. Sugarbaker

- Chapter 6 Active Specific Immunotherapy as an Adjunct to
the Treatment of Metastatic Solid Tumors: Present
and Future Prospects

*Marc E. Key, Herbert C. Hoover, Jr., and
Michael G. Hanna, Jr.*